Results From a Phase 2 Randomized Double-blind Placebo-Controlled Study (VANILLA)

Tom Willigoss, PhD; Lisa Squassante, MSc; Federico Bolognani, MD, PhD; Janice Smith, PhD; Lorraine Murtagh, PhD; Filippo Fontoura, MD, PhD; Omar Kowaja, MD; Daniel Umbricht, MD; Keith Scandone, MD; and Maria del Valle Rubio, MPH

Background

Objectives

- To fully determine the effect of balovaptan on HRQoL, ongoing and future studies will be critical to validate this signal and to extend these findings across the age and gender spectrum of children with ASD

Methods

- The PedsQL Total score showed positive trends of improvement in HRQoL, with balovaptan 10 mg compared with placebo in all domains
- Trends in improvement in the PedsQL Cognitive Functioning Scale were observed with balovaptan 10 mg compared with placebo, suggesting meaningful improvements in HRQoL
- To fully delineate the effect of balovaptan on HRQoL, ongoing and future studies will be critical to validate this signal and to extend these findings across the age and gender spectrum of children with ASD

Conclusions

- The PedsQL Total score showed positive trends of improvement in HRQoL with balovaptan 10 mg compared with placebo in all domains
- Trends in improvement in the PedsQL Cognitive Functioning Scale were observed with balovaptan 10 mg compared with placebo, suggesting meaningful improvements in HRQoL